The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Health for Life Capital fund, startups are often financed by Seventure Partners, Lundbeckfonden Ventures, Innovation Network Corporation of Japan. The meaningful sponsors for the fund in investment in the same round are Seventure Partners, Tao Capital Partners, Shinsei Corporate Investment Limited. In the next rounds fund is usually obtained by Tyson Ventures, Taiho Ventures, TMI Investments BV.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Organic Food. Among the various public portfolio startups of the fund, we may underline Axial Biotherapeutics, MycoTechnology, ENTEROME Bioscience The fund has no exact preference in some founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager.
The important activity for fund was in 2017. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in less than 2 investment rounds annually.
Related Funds
| Fund Name | Location |
| Amador Holdings | Ciudad De Panamá, Panamá, Panama |
| Arctos Capital | California, San Francisco, United States |
| Cameleon Invest | France, Ile-de-France, Paris |
| China Health Industry Investment Fund | - |
| Cure Kids Ventures | - |
| Ellis Accelerator | New York, New York, United States |
| Eos Capital | Khomas, Namibia, Windhoek |
| FullCycle | California, Los Angeles, United States |
| Hangzhou Kang Sheng Health Management | - |
| Hanwha Asset Management | Seoul, Seoul-t'ukpyolsi, South Korea |
| Jinan Tongtai | China, Jinan, Shandong |
| MiMo Capital | Florida, Miami, United States |
| Qicheng Chuang Tou | China, Dongguan, Hebei |
| Rongtong Capital Management | China, Guangdong, Shenzhen |
| Russian Foundation for Technological Development | - |
| SARORAS Private Capital | New York, New York, United States |
| Sectoral Asset Management | Canada, Montréal, Quebec |
| Xinganxian Media Investment | China, Hangzhou, Zhejiang |
| Xingfen Yaotu | China, Zhejiang, Zhoushan |
| Yifan Capital | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Axial Biotherapeutics | $25M | 27 Feb 2019 | Massachusetts, United States | ||
MycoTechnology | $42M | 29 Aug 2017 | Aurora, Colorado, United States | ||
ENTEROME | $17M | 20 Apr 2016 | Ile-de-France |
– Vedanta Biosciences, Inc. from Cambridge, MA develops new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks.
– The company closed a $68m Series D financing.
– The round was led by affiliates of Magnetar Capital with participation from Verition Fund Management, Fosun Health Capital, co-founder PureTech Health (Nasdaq: PRTC, LSE: PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corporation, SymBiosis LLC, Shumway Capital, Health for Life Capital (Seventure Partners), and other institutional investors.
– The company plans to use the funds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrentCDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Axial Biotherapeutics | $25M | 27 Feb 2019 | Massachusetts, United States | ||
MycoTechnology | $42M | 29 Aug 2017 | Aurora, Colorado, United States | ||
ENTEROME | $17M | 20 Apr 2016 | Ile-de-France |
